Press & Media
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer
Mark Leiser from HemOnc Today discusses results from ArteraAI’s prognostic MMAI model that were presented by Daniel Spratt, M [...]
Press & Media
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate C [...]
Press & Media
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of ArteraAI, discusses how AI can support the ACS’ IMPACT initiative and other possibilities [...]
Press & Media
An Introduction to ArteraAI’s Cloud Infrastructure
Introduction ArteraAI was founded on the idea that cutting edge technology can be used to completely transform the medical fi [...]